A Study of PER-001 in Participants With Open-Angle Glaucoma

This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.

Inclusion Criteria: For Phase 1 and Phase 2a: * Must be ≥ 18 years of age at the time of signing the informed consent * A negative pregnancy test for females of childbearing potential at Screening (serum) and Day 1 (urine). * IOP 6 to 25 mmHg (inclusive) at Screening in potentially eligible eye(s) Phase 1: * Best corrected visual acuity (BCVA) LogMAR score 1.0 or better at Screening in at least one eye and prior to randomization at Day 1 in the study eye * Diagnosis of advanced or severe primary OAG including normal tension, pseudoexfoliation and pigment dispersion Phase 2: * BCVA LogMAR score 0.5 or better at Screening in at least one eye and prior to randomization at Day 1 in the study eye * Primary OAG that is progressing in the study eye Exclusion Criteria: * Blood pressure \>140/90 mmHg or \